Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic … Read more
Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) - Total Assets
Latest total assets as of June 2025: CN¥3.12 Billion CNY
Based on the latest financial reports, Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443) holds total assets worth CN¥3.12 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Total Assets Trend (2021–2024)
This chart illustrates how Chongqing Genrix Biopharmaceutical Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Chongqing Genrix Biopharmaceutical Co. Ltd. A's total assets of CN¥3.12 Billion consist of 83.4% current assets and 16.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 64.7% |
| Accounts Receivable | CN¥12.01 Million | 0.4% |
| Inventory | CN¥50.15 Million | 1.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥43.59 Million | 1.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Chongqing Genrix Biopharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongqing Genrix Biopharmaceutical Co. Ltd. A's current assets represent 83.4% of total assets in 2024, an increase from 52.8% in 2021.
- Cash Position: Cash and equivalents constituted 64.7% of total assets in 2024, up from 1.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 1.6% of total assets.
Chongqing Genrix Biopharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Chongqing Genrix Biopharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Chongqing Genrix Biopharmaceutical Co. Ltd. A generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Chongqing Genrix Biopharmaceutical Co. Ltd. A is currently not profitable relative to its asset base.
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.84 | 20.50 | 20.50 |
| Quick Ratio | 5.70 | 20.06 | 20.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.14 Billion | CN¥ 2.63 Billion | CN¥ 2.63 Billion |
Chongqing Genrix Biopharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Chongqing Genrix Biopharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.59 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -12.5% |
| Total Assets | CN¥3.15 Billion |
| Market Capitalization | $413.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chongqing Genrix Biopharmaceutical Co. Ltd. A's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Chongqing Genrix Biopharmaceutical Co. Ltd. A's assets decreased by 12.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chongqing Genrix Biopharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total assets of Chongqing Genrix Biopharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion | -12.49% |
| 2023-12-31 | CN¥3.59 Billion | +273.62% |
| 2022-12-31 | CN¥962.11 Million | -4.06% |
| 2021-12-31 | CN¥1.00 Billion | -- |